References
- Liu-SeifertHAdamsDHKinonBJDiscontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugsBMC Med200532116375765
- DunayevichEAscher-SvanumHZhaoFLonger time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorderJ Clin Psychiatry2007681163117117854239
- ChuePLong-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychoticNeuropsychiatr Dis Treat20073133919300536
- WeidenPZygmuntAMedication noncompliance in schizophrenia. Part I. AssessmentJ Pract Psychiatry Behav Health19973106110
- CramerJARosenheckRCompliance with medication regimens for mental and physical disordersPsychiatr Serv1998491962019575004
- SimpsonGMA brief history of depot neurolepticsJ Clin Psychiatry199845346143745
- DavisJMMatalonLWatanabeMDBlakeLDepot antipsychotic drugs. Place in therapyDrugs1994477417737520856
- KaneJMAgugliaEAltamuraACGuidelines for depot antipsychotic treatment in schizophreniaEur Neuropsychopharmacol1998855669452941
- ShiLAscher-SvanumHZhuBFariesDMontgomeryWMarderSRCharacteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophreniaPsychiatr Serv20075848248817412849
- HaddadPMTaylorMNiazOSFirst-generation antipsychotic long-acting injections vs oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studiesBr J Psychiatry Suppl200952S20S2819880913
- TaylorMCurrieALloydKPriceMPeperellKImpact of risperidone long acting injection on resource utilization in psychiatric secondary careJ Psychopharmacol20082212813118308820
- NiazOSHaddadPMThirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient careActa Psychiatr Scand2007116364617559599
- TaylorDMYoungCLMaceSPatelMXEarly clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patientsJ Clin Psychiatry2004651076108315323592
- YoungCLTaylorDMHealth resource utilization associated with switching to risperidone long-acting injectionActa Psychiatr Scand2006114142016774656
- TaylorDFischettiCSparshattAThomasABisharaDCorneliusVRisperidone long-acting injection: a 6-year mirror-image study of healthcare resource useActa Psychiatr Scand20091209710119207128
- FullerMShermockKRussoPHospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare SystemJ Med Econ20091231732419817665
- Thomson HealthcareMarketScan® research databases user guide and database dictionaryAnn Arbor, MIThomson Healthcare, Inc2007
- RamseySWillkeRBriggsAGood research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force reportValue Health2005852153316176491
- FariesDEPengXObenchainRLCosts and cost effectiveness analysis using propensity score bin bootstrappingFariesDELeonACHaroJMObenchainRLAnalysis of Observational Health Care Data Using SASCary, NCSAS Institute2010
- FariesDENyhuisAWAscher-SvanumHMethodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study exampleCost Eff Resour Alloc200971119473545
- ByerlyMJNakoneznyPALescouflairEAntipsychotic medication adherence in schizophreniaPsychiatr Clin North Am20073043745217720031
- KeithSJKaneJMPartial compliance and patient consequences in schizophrenia: our patients can do betterJ Clin Psychiatry2003641308131514658944